| INTRODUCTION
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC).
1,2 New and more effective therapies for HCV may have changed the all-cause and cause-specific mortality. Instead of dying of HCV, persons who have cleared HCV may be more likely to die from other conditions such as malignancies (other than HCC), cardiovascular disease, accidents, illicit drug overdose, suicide and other infections. 2 Because chronic hepatitis C progresses slowly, these trends may emerge slowly, and some have predicted that liver-related complications and deaths will continue to increase for at least another decade. 3, 4 For example, the Global Burden of Disease Study found that the absolute number of deaths attributable to hepatitis C increased from 303 000 in 1990 to 704 000 in 2013. 
| MATERIALS AND METHODS

| Trends in cause-specific mortality rates in the SFSO death registry
The SFSO has monitored the number and causes of death in defined these sets by consensus.
We calculated time trends (with 95% confidence intervals) in crude and age-standardized mortality rates. Age-standardized rates were calculated by direct standardization. We used the official SFSO permanent resident population data as the annual denominator. We calculated the mid-year population for each year by averaging the end of year population in 1 year with the end of year population of the previous year. We grouped age into 5-year categories (0-4, 5-9, …, 85+). For direct standardization, we used as reference the mid-2014 estimated permanent resident population.
| The Swiss Hepatitis C Cohort Study
To analyse potential under-reporting of HCV-related mortality in the SFSO registry, we compared the causes of death the SFSO reported 
| Inclusion criteria and definitions
All persons enrolled into the SCCS were eligible for our analysis. Lost to follow-up (LTFU) was defined as "not seen for at least two years after the last visit to the clinic (excluding persons who have died)."
Only persons who were registered more than two years before the database closed could be considered LTFU (on 31 December 2014).
| Linkage with the SFSO death registry
To compare the causes of death reported by the SCCS with those of the official death registry of the SFSO, we used data from the Swiss National Cohort SNC. 10, 11 In short, the SNC is a cohort of all Swiss residents which linked records from the 1990 and 2000 censuses to the deaths from the SFSO death registry. Deceased persons of the SCCS were anonymously linked with the mortality data of the SNC, using probabilistic record linkage. 12 We used date of birth, date of death, gender and nationality (Swiss vs non-Swiss) to link records and allowed for typos in the linkage variables. We also used spatial information to improve the linkage, assigning the SCCS clinics and place of residence at time of death to one of the seven nomenclature of territorial units for statistics areas of Switzerland. 13 We included deaths that occurred between 18 September 2000 (start of the SCCS) and the end of 2014. We used G-Link software, developed by Statistics Canada, 14 for linkage. We identified possible matches based on probability weights, and set the threshold so that only highly probable links were accepted. We compared characteristics between persons successfully linked and persons with failed linkage.
We determined how many deceased persons in the SCCS (related or unrelated to HCV, or cause of death unknown) had hepatitis C listed on their SFSO death certificate. We used the same definitions of (possibly) hepatitis C-related mortality: (i) HCV (B17.1 or B18.2) as primary cause; (ii) HCV anywhere on the SFSO death certificate; (iii) first set of additional causes anywhere on the SFSO death certificate;
and (iv) second set of additional causes anywhere on the SFSO death certificate.
All analyses were performed with Stata version 14 (StataCorp, College Station, TX, USA). . Age-standardized rates were very similar to crude rates (data not shown). Table 1 shows the characteristics of all the persons in the SCCS and of deceased persons who could or could not be linked to the SFSO registry. At enrolment, persons in the SCCS were mostly male (63%), Swiss nationals (73%) and had a median age of 44 years (IQR: 37-52 years). Slightly over half were former (11%) or current (44%) injecting drug users, a third reported previous or ongoing heavy alcohol consumption (>40 g/day) and 15% had liver cirrhosis.
| RESULTS
| SFSO mortality rates
| Characteristics of persons in the SCCS
A total of 941 (20.6%) persons were lost to follow-up before the database closed at the end of 2014. Deceased persons who could and those who could not be linked to the SFSO registry had similar characteristics. 
| Linkage SCCS-death registry
| Comparison between causes of death reported by the SCCS with the causes reported by the SFSO death registry
In the death registry, hepatitis C was mentioned as cause of death for a minority of persons (either as primary cause or anywhere on the SFSO death certificate), showing substantial under-reporting (Table 2 ). Of the 363 SCCS deaths that could be linked, only for 13 (3.6%), the SFSO registry mentioned hepatitis C as primary cause of death, while for 138 (38.0%), hepatitis C was mentioned anywhere (Table 2) Finally, among the 100 persons whose cause of death was unknown in the SCCS, the SFSO certificate reported that 5 (5.0%) died of HCV as primary cause, and HCV was reported anywhere for 30 (30.0%).
These numbers increased to 42 (42.0%) after considering the first set of causes of death potentially related to HCV (mentioned anywhere on the death certificate) and 44 (44.0%) for the second set. The overall pattern of mortality for HCV, HBV and HIV was similar in the United States and Switzerland, but there were some important differences. In 1999, HIV-related mortality was much lower in Switzerland than in the United States 7 (about 2.5/100 000 vs 6.0/100 000) but both subsequently declined at a similar pace. The introduction of effective combination therapy caused the initial steep decline in HIV-related mortality in Switzerland; thereafter, the decline was more gentle, but continuous, probably because antiretroviral drugs continued to become more effective and were better tolerated. 15, 16 The steep decline of HIV-related mortality in Switzerland may also explain why HCV-related mortality rose higher than HIV-related mortality sooner in Switzerland (2000) and 1974. 20 We are not sure why we did not see an increase in HCVrelated mortality in Switzerland in the past years. Perhaps the quality of care has improved over time, the simulation model was not accurate, or mortality was under-reported. Or, the increase may simply be For the other deaths (sets 1 and 2) possibly related to HCV, it is also difficult to determine the proportion caused by HCV.
| DISCUSSION
Our study was strengthened by the two complementary data sources we used to analyse HCV-related mortality in Switzerland.
SFSO data are nationwide and include all deaths in Switzerland. The SCCS data set allowed us to compare and validate causes of death.
The SCCS covers most of Switzerland and includes probably >10%
of the estimated 36 000-43 000 HCV-infected persons. 25 The characteristics of the persons in the SCCS are similar to those reported by the national surveillance data of the Federal Office of Public Health, 9,30 so our findings can be generalized to other HCV-infected persons in Switzerland. However, the SCCS also has limitations.
It includes a disproportionate high number of persons from large university hospitals at an advanced stage of the disease. 9 Cause of death was unknown for 27.5% of all deceased persons in the SCCS who could be linked. The reason for these missing values was not documented, but it was often not possible to obtain the medical records or to reach the personal physician. These observations limit our comparison of causes of death between the two data sources.
Moreover, linkage might also introduce some bias. 
